MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials

Posttraumatic stress disorder (PTSD) is a serious chronic condition with limited effective treatments. MDMA-assisted psychotherapy (MDMA-AT) has shown promise in earlier trials, but the FDA recently voted against recommending it due to risk-benefit concerns. This systematic review of seven randomized controlled trials involving 280 adults with PTSD (160 received MDMA, 120 received placebo) found that five of six studies (83.3%) reported significantly greater PTSD symptom reduction with MDMA-AT compared to placebo. Across studies, 41.7% to 85.7% of MDMA recipients no longer met PTSD criteria post-treatment versus 25.0% to 33.3% in placebo groups. The treatment was well-tolerated. The findings support MDMA-AT as a potential treatment, but additional research with ethical oversight should inform FDA approval.

Study at a glance

Abstract

Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxymethamphethamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promise in phase 2 and phase 3 clinical trials, with many research participants reporting significant reductions in PTSD symptoms. However, the Federal Drug Administration (FDA) recently voted against recommending MDMA-AT, citing concerns about its risk-benefit profile. This systematic review aimed to assess current evidence from randomized control trials (RCTs) on the safety and efficacy of MDMA-AT for adults with PTSD to determine if it warrants consideration for approval. Two articles identified were excluded from our analysis due to their recent retraction from publication. In total, seven RCTs were identified, including 280 adult participants with PTSD (160 received MDMA; 120 received placebo). Data were independently reviewed, focusing on PTSD symptom reduction and safety. Of the six studies included in the efficacy analysis, five (83.3%) found significantly improved PTSD symptoms in the MDMA groups compared to placebo groups. In addition, 41.7% to 85.7% of participants receiving MDMA-AT no longer met PTSD criteria post-treatment, compared to 25.0% to 33.3% reported for placebo groups. In addition, the treatment appeared well-tolerated. These findings support the potential of MDMA-AT as a viable treatment option for the symptoms of PTSD, though additional research with strict ethical oversight should inform FDA approval.